[SCHEDULE 13G/A] CytomX Therapeutics, Inc. Amended Passive Investment Disclosure
Kynam Capital discloses 9.96% stake in CytomX
Kynam Capital Management, LP, together with Kynam Capital Management GP, LLC and Yue Tang, reports beneficial ownership of CytomX Therapeutics, Inc. common stock.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Kynam Capital Management, LP, together with Kynam Capital Management GP, LLC and Yue Tang, reports beneficial ownership of CytomX Therapeutics, Inc. common stock. The group has shared voting and dispositive power over 21,703,093 shares, representing 9.96% of the outstanding common stock, with no sole voting or dispositive power reported by any of the filers.
Key Figures
Beneficial ownership percentage:9.96 %Shares with shared voting power:21,703,093 sharesShares with shared dispositive power:21,703,093 shares
3 metrics
Beneficial ownership percentage9.96 %Percentage of CytomX common stock reported as beneficially owned by the Kynam Capital group
Shares with shared voting power21,703,093 sharesCytomX common shares over which the filers have shared voting power
Shares with shared dispositive power21,703,093 sharesCytomX common shares over which the filers have shared power to dispose
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting powerfinancial
"Shared Voting Power 21,703,093.00 7 | Sole Dispositive Power 0.00 8 | Shared Dispositive Power"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of CytomX Therapeutics (CTMX) does Kynam Capital report owning?
Kynam Capital and related filers report beneficial ownership of 9.96% of CytomX Therapeutics’ common stock. This stake is held with shared voting and dispositive power over the reported shares.
How many CytomX Therapeutics (CTMX) shares does Kynam Capital control?
Kynam Capital, its general partner, and Yue Tang report shared voting and dispositive power over 21,703,093 shares of CytomX Therapeutics common stock, reflecting their disclosed beneficial ownership position.
Does Kynam Capital have sole voting power over any CTMX shares?
No. The filing states that Kynam Capital, its GP, and Yue Tang each have 0 shares with sole voting power and instead hold shared voting power over 21,703,093 shares of CytomX common stock.
Who are the reporting persons in the CytomX (CTMX) Schedule 13G/A?
The reporting persons are Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. All are associated with the reported 9.96% beneficial ownership of CytomX Therapeutics common stock.
What type of securities in CytomX (CTMX) are reported in this Schedule 13G/A?
The filing covers Common Stock, $0.00001 par value per share of CytomX Therapeutics, Inc., identified by CUSIP 23284F105, held with shared voting and dispositive power by the reporting group.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
CytomX Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.00001 par value per share
(Title of Class of Securities)
23284F105
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
23284F105
1
Names of Reporting Persons
Kynam Capital Management, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
21,703,093.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
21,703,093.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.96 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP Number(s):
23284F105
1
Names of Reporting Persons
Kynam Capital Management GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
21,703,093.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
21,703,093.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.96 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
23284F105
1
Names of Reporting Persons
Yue Tang
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
21,703,093.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
21,703,093.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.96 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
CytomX Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CALIFORNIA
94080
Item 2.
(a)
Name of person filing:
Kynam Capital Management, LP
Kynam Capital Management GP, LLC
Yue Tang
(b)
Address or principal business office or, if none, residence:
221 ELM ROAD
PRINCETON, New Jersey
08540
(c)
Citizenship:
Kynam Capital Management, LP - DELAWARE
Kynam Capital Management GP, LLC - DELAWARE
Yue Tang - UNITED STATES
(d)
Title of class of securities:
Common Stock, $0.00001 par value per share
(e)
CUSIP No.:
23284F105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
0
(b)
Percent of class:
9.96 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Kynam Capital Management, LP - 0
Kynam Capital Management GP, LLC - 0
Yue Tang - 0
(ii) Shared power to vote or to direct the vote:
Kynam Capital Management, LP - 21,703,093
Kynam Capital Management GP, LLC - 21,703,093
Yue Tang - 21,703,093
(iii) Sole power to dispose or to direct the disposition of:
Kynam Capital Management, LP - 0
Kynam Capital Management GP, LLC - 0
Yue Tang - 0
(iv) Shared power to dispose or to direct the disposition of:
Kynam Capital Management, LP - 21,703,093
Kynam Capital Management GP, LLC - 21,703,093
Yue Tang - 21,703,093
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
